Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
Negma Group has converted 140 convertible bonds in Oxurion resulting in a EUR 350,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment[1] that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidates that are targeting potential market opportunities of over USD 12 billion.
Leuven, BE, Boston, MA, US – December 30, 2021 – 07.00 AM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 203,488 new ordinary shares on December 23 (as listed on December 27), 2021, for a total amount of EUR 350,000 (including an issue premium amounting to EUR 56,977.28), as the result of the conversion of 140 convertible bonds pursuant to the Capital Commitment entered into with Negma Group.
Following completion of the capital increase, the total number of shares issued by Oxurion amounts to 39,067,284 outstanding ordinary shares carrying voting rights (compared to 38,863,796 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
· Share capital (EUR) |
56,442,441.96 |
· Total number of securities with voting rights (all ordinary shares) |
39,067,284 |
· Total number of ordinary shares (= denominator) |
39,067,284 |
· Number of outstanding rights to subscribe to securities carrying voting rights not yet issued: |
|
|
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506